Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study

Objective Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. Methods The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Medi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bijun Fan, Xiaoming Tan, Yueyan Lou, Yu Zheng, Liyan Zhang, Xueling Wu
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Acceso en línea:https://doaj.org/article/7ed1120a6a494c16846682beb52de200
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7ed1120a6a494c16846682beb52de200
record_format dspace
spelling oai:doaj.org-article:7ed1120a6a494c16846682beb52de2002021-11-12T01:03:23ZPrognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study1473-230010.1177/03000605211046173https://doaj.org/article/7ed1120a6a494c16846682beb52de2002021-10-01T00:00:00Zhttps://doi.org/10.1177/03000605211046173https://doaj.org/toc/1473-2300Objective Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. Methods The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Medicine, Shanghai Jiaotong University were retrospectively reviewed. The optimal cutoff prognostic nutritional index (PNI) value for predicting efficacy was determined according to receiver operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were calculated and compared using the Kaplan–Meier method and log‐rank test. The prognostic values of each variable were evaluated with univariate and multivariate Cox proportional hazard regression analyses. Results The overall disease control rate of 44 patients with lung cancer was 93.2% (41/44). The median PFS was 5.0 months (95% [confidence interval] CI: 2.2–7.8), and the median OS was 6.5 months (95% CI: 3.6–9.3). The multivariate analysis results indicated that hand–foot syndrome and high PNI values were independent protective factors of PFS and OS. Conclusions Anlotinib was effective in treating locally advanced or advanced lung cancer. High pretreatment PNI scores and the presence of hand–foot syndrome after treatment were independent prognostic markers for favorable OS and PFS.Bijun FanXiaoming TanYueyan LouYu ZhengLiyan ZhangXueling WuSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Bijun Fan
Xiaoming Tan
Yueyan Lou
Yu Zheng
Liyan Zhang
Xueling Wu
Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
description Objective Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. Methods The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Medicine, Shanghai Jiaotong University were retrospectively reviewed. The optimal cutoff prognostic nutritional index (PNI) value for predicting efficacy was determined according to receiver operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were calculated and compared using the Kaplan–Meier method and log‐rank test. The prognostic values of each variable were evaluated with univariate and multivariate Cox proportional hazard regression analyses. Results The overall disease control rate of 44 patients with lung cancer was 93.2% (41/44). The median PFS was 5.0 months (95% [confidence interval] CI: 2.2–7.8), and the median OS was 6.5 months (95% CI: 3.6–9.3). The multivariate analysis results indicated that hand–foot syndrome and high PNI values were independent protective factors of PFS and OS. Conclusions Anlotinib was effective in treating locally advanced or advanced lung cancer. High pretreatment PNI scores and the presence of hand–foot syndrome after treatment were independent prognostic markers for favorable OS and PFS.
format article
author Bijun Fan
Xiaoming Tan
Yueyan Lou
Yu Zheng
Liyan Zhang
Xueling Wu
author_facet Bijun Fan
Xiaoming Tan
Yueyan Lou
Yu Zheng
Liyan Zhang
Xueling Wu
author_sort Bijun Fan
title Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
title_short Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
title_full Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
title_fullStr Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
title_full_unstemmed Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
title_sort prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
publisher SAGE Publishing
publishDate 2021
url https://doaj.org/article/7ed1120a6a494c16846682beb52de200
work_keys_str_mv AT bijunfan prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy
AT xiaomingtan prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy
AT yueyanlou prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy
AT yuzheng prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy
AT liyanzhang prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy
AT xuelingwu prognosticfactorsofpatientswithadvancedlungcancertreatedwithanlotinibaretrospectivecohortstudy
_version_ 1718431299195109376